Healthpeak Properties™ Reports Third Quarter 2020 Results
THIRD QUARTER 2020 FINANCIAL PERFORMANCE AND RECENT HIGHLIGHTS
– The COVID-19 pandemic continues to evolve. In order to provide more up-to-date information about the impact of COVID-19 on Healthpeak, we have provided certain key operating metrics through
– Dispositions:
- In various stages on the sales of more than
$4 billion of SHOP and NNN transactions: - In July -
November 2020 , closed on the sales of 14 SHOP and NNN assets generating proceeds of approximately$100 million . - Approximately
$1.5 billion under binding and non-binding purchase agreements across 8 separate transactions. - Approximately
$2 billion under letters of intent across 6 separate transactions. - The majority of the remaining SHOP and NNN assets are actively being marketed for sale.
- If the various sales are completed, we expect:
- SHOP assets: a Trailing Twelve Month Pre-COVID (
04/01/19 - 03/31/20 ) weighted average cash capitalization rate in the high 5% range and a third quarter annualized weighted average cash capitalization rate of approximately 3%. - NNN assets: a third quarter annualized weighted average lease yield in the high 7% range and EBITDAR yield in the high 5% range.
- During the quarter, closed on the sales of
$15 million of medical office and other assets.
– Acquisitions:
- In
October 2020 , executed a definitive agreement to acquireCambridge Discovery Park , a 607,000 square foot life science campus in theWest Cambridge submarket ofBoston, MA for$664 million in an off-market transaction, which represents stabilized cash and GAAP capitalization rates of 5% and 6.5%, respectively. The site includes a future densification opportunity of approximately 100,000 square feet. - In
October 2020 , executed a definitive agreement to acquire approximately 12 acres of land for$128 million in an off-market transaction. The acquisition sites are located inSouth San Francisco, CA , adjacent to two sites currently held by Healthpeak as land for future development:Forbes Research Center ("Forbes") and Modular Labs III. Healthpeak intends to entitle the acquisition sites for a new development of at least 500,000 square feet, which could join with our adjacent sites to create a multi-phase, scalable development campus totaling 1 million square feet or more. - In
October 2020 , acquired a 7-property medical office portfolio, totaling 439,000 square feet, for$169 million , which represents year-one cash and GAAP capitalization rates of 5.5% and 5.6%, respectively. Six of the seven properties are on-campus and all the properties are anchored by a #1 or #2 local health system. - In
July 2020 , acquired a two-story, 107,000 square foot medical office building inScottsdale, AZ for$27 million in an off-market transaction, which represents year-one cash and GAAP capitalization rates of 7.1% and 7.7%, respectively.
– Development:
- In
September 2020 , signed a 10-year 118,000 square feet lease at ourBoardwalk development project inSan Diego, CA. The development is now 100% pre-leased, with initial occupancy expected in late 2021. - In
September 2020 , commenced construction on101 CambridgePark Drive , a 159,000 square foot life science development project, located in theWest Cambridge submarket ofBoston, MA , with estimated total spend of approximately$174 million . - In
September 2020 , delivered a 119,000 square foot, six-story medical office building inBrentwood, TN. The development was 49% leased to HCA Healthcare ("HCA") upon delivery. - In
August 2020 , delivered a 70,000 square foot, four-story Class A medical office building located on theOgden Regional Medical Center campus inOgden, Utah . The development was 69% leased upon delivery and is 78% leased today.
– As of
– Replaced Board of Directors age 75 retirement policy with a Director term limit of 15 years.
– Declared quarterly common stock cash dividend of
– Established new corporate headquarters in
– Received "Prime" rating from ISS ESG Corporate Rating, recognizing top ESG performance within our sector; nominated for the Corporate Governance Awards 2020 - Best Proxy Statement (
THIRD QUARTER COMPARISON
|
Three Months Ended |
Three Months Ended |
|||||||||||||||
|
(in thousands, except per share amounts) |
Amount |
Per Share |
Amount |
Per Share |
||||||||||||
|
Net income (loss), diluted |
$ |
(63,768) |
$ |
(0.12) |
$ |
(46,249) |
$ |
(0.09) |
||||||||
|
NAREIT FFO, diluted |
164,603 |
0.31 |
183,266 |
0.37 |
||||||||||||
|
FFO as Adjusted, diluted |
215,381 |
0.40 |
222,160 |
0.44 |
||||||||||||
|
AFFO, diluted |
183,791 |
191,922 |
||||||||||||||
NAREIT FFO, FFO as Adjusted, AFFO, Same-Store Cash NOI, Net Debt and Adjusted EBITDAre are supplemental non-GAAP financial measures that we believe are useful in evaluating the operating performance and financial position of real estate investment trusts (see the "Funds From Operations" and "Adjusted Funds From Operations" sections of this release for additional information). See "
SAME-STORE ("SS") OPERATING SUMMARY
The table below outlines the year-over-year three-month and year-to-date SS Cash NOI growth:
|
Year-Over-Year Total SS Portfolio Cash NOI Growth |
||||
|
Three Month |
Year-To-Date |
% of SS |
||
|
Medical office |
3.3% |
2.3% |
46.8% |
|
|
Life science |
5.5% |
5.7% |
38.5% |
|
|
Senior housing(1)(2) |
(6.3)% |
(5.8)% |
10.5% |
|
|
Other non-reportable segments ("Other") |
0.8% |
3.0% |
4.1% |
|
|
Total Portfolio(1)(2) |
2.8% |
2.7% |
100.0% |
|
|
(1) |
Same-Store year-over-year three-month Portfolio Cash NOI growth includes identifiable COVID-19 expenses of |
|
|
(2) |
Same-Store year-over-year year-to-date Portfolio Cash NOI growth includes identifiable COVID-19 expenses of |
ACQUISITIONS
In
The 607,000 square foot campus is located walking distance from Healthpeak's
The transaction strengthens Healthpeak's leading market share in
In
Upon closing of the acquisition, Healthpeak intends to entitle the sites for future development as a life science campus that, when combined with Healthpeak's Forbes and Modular Labs III sites, could allow for a campus with an estimated minimum size of approximately 1 million square feet over 20 acres. The future developments will strengthen Healthpeak's leading market position in
MIDWEST MEDICAL OFFICE PORTFOLIO ACQUISITION
In
The transaction supports Healthpeak's MOB growth strategy of investing in on-campus and highly anchored properties affiliated with #1 or #2 local hospitals and health systems.
In
The property is currently 96% leased to four tenants and has a weighted average remaining lease term of 5 years with 2% average annual escalators.
Located adjacent to the
DEVELOPMENT UPDATES
101 CAMBRIDGEPARK DRIVE
In
Totaling approximately 159,000 square feet, the five-story Class A laboratory building will allow Healthpeak to create a 450,000 square foot flagship campus in
Completion is expected in third quarter of 2022, and upon stabilization, the development is projected to generate an estimated yield on cost of 7.5%.
MEDICAL OFFICE DEVELOPMENT PROGRAM WITH HCA
Brentwood : InSeptember 2020 , delivered a 119,000 square foot, six-story medical office building inBrentwood, TN. The$37 million development was 49% leased to HCA upon delivery and is projected to generate a stabilized yield in the low to mid 8% range.Ogden : InAugust 2020 , delivered a 70,000 square foot, four-story Class A medical office building located on theOgden Regional Medical Center campus inOgden, Utah . The$18 million development was 69% leased upon delivery and is 78% leased today. The property is projected to generate a stabilized yield in the low to mid 7% range.
THE BOARDWALK DEVELOPMENT LEASING
In
Initial occupancy is expected in the fourth quarter of 2021, and upon stabilization, the campus is projected to generate an estimated yield on cost of 7.1%.
BOARD OF DIRECTORS RETIREMENT POLICY UPDATE
In
DIVIDEND
On
NEW CORPORATE HEADQUARTERS
In
ESG
Healthpeak's position as a leader in environmental, social and governance (ESG) performance has been recognized by various organizations around the world. For the ninth consecutive year, Healthpeak was named a constituent in the FTSE4Good Index. Healthpeak also received "Prime" rating from ISS ESG Corporate Rating for its top ESG performance. Healthpeak was also nominated for the Corporate Governance Awards 2020 - Best Proxy Statement (
2020 OUTLOOK UPDATE
Please see pages 45-47 in the Third Quarter 2020 Supplemental Report for a revised outlook and earnings framework.
COMPANY INFORMATION
Healthpeak has scheduled a conference call and webcast for
ABOUT HEALTHPEAK
FORWARD-LOOKING STATEMENTS
Statements in this release that are not historical facts are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements include, among other things, statements regarding our and our officers' intent, belief or expectation as identified by the use of words such as "may," "will," "project," "expect," "believe," "intend," "anticipate," "seek," "target," "forecast," "plan," "potential," "estimate," "could," "would," "should" and other comparable and derivative terms or the negatives thereof. Examples of forward-looking statements include, among other things: (i) statements regarding timing, outcomes and other details relating to current, pending or contemplated acquisitions, dispositions, transitions, developments, redevelopments, joint venture transactions, leasing activity, capital recycling plans, financing activities, or other transactions discussed in this release; (ii) the payment of a quarterly cash dividend; and (iii) statements regarding the impact of the COVID-19 pandemic on our business, financial condition and results of operations. Pending dispositions, including those subject to binding agreements, remain subject to closing conditions and may not close within the anticipated timeframes or at all. Forward-looking statements reflect our current expectations and views about future events and are subject to risks and uncertainties that could significantly affect our future financial condition and results of operations. While forward-looking statements reflect our good faith belief and assumptions we believe to be reasonable based upon current information, we can give no assurance that our expectations or forecasts will be attained. Further, we cannot guarantee the accuracy of any such forward-looking statement contained in this release, and such forward-looking statements are subject to known and unknown risks and uncertainties that are difficult to predict. These risks and uncertainties include, but are not limited to: the severity and duration of the COVID-19 pandemic; actions that have been taken and may continue to be taken by governmental authorities to contain the COVID-19 outbreak or to treat its impact; the impact of the COVID-19 pandemic and health and safety measures taken to reduce the spread; operational risks associated with third party management contracts, including the additional regulation and liabilities of our RIDEA lease structures; the ability of our existing and future tenants, operators and borrowers to conduct their respective businesses in a manner sufficient to maintain or increase their revenues and manage their expenses in order to generate sufficient income to make rent and loan payments to us and our ability to recover investments made, if applicable, in their operations; the imposition of laws or regulations prohibiting the eviction of our tenants, including new governmental efforts in response to COVID-19; the financial condition of our existing and future tenants, operators and borrowers, including potential bankruptcies and downturns in their businesses, and their legal and regulatory proceedings, which results in uncertainties regarding our ability to continue to realize the full benefit of such tenants' and operators' leases and borrowers' loans; our concentration in the healthcare property sector, particularly in senior housing, life sciences and medical office buildings, which makes our profitability more vulnerable to a downturn in a specific sector than if we were investing in multiple industries; the effect on us and our tenants and operators of legislation, executive orders and other legal requirements, including compliance with the Americans with Disabilities Act, fire, safety and health regulations, environmental laws, the Affordable Care Act, licensure, certification and inspection requirements, and laws addressing entitlement programs and related services, including Medicare and Medicaid, which may result in future reductions in reimbursements or fines for noncompliance; our ability to identify replacement tenants and operators and the potential renovation costs and regulatory approvals associated therewith; the risks associated with property development and redevelopment, including costs above original estimates, project delays and lower occupancy rates and rents than expected; the potential impact of uninsured or underinsured losses, including as a result of hurricanes, earthquakes and other natural disasters, pandemics such as COVID-19, acts of war and/or terrorism and other events that may cause such losses and/or performance declines by us or our tenants and operators; the risks associated with our investments in joint ventures and unconsolidated entities, including our lack of sole decision making authority and our reliance on our partners' financial condition and continued cooperation; competition for the acquisition and financing of suitable healthcare properties as well as competition for tenants and operators, including with respect to new leases and mortgages and the renewal or rollover of existing leases; our or our counterparties' ability to fulfill obligations, such as financing conditions and/or regulatory approval requirements, required to successfully consummate acquisitions, dispositions, transitions, developments, redevelopments, joint venture transactions or other transactions; our ability to achieve the benefits of acquisitions or other investments within expected time frames or at all, or within expected cost projections; the potential impact on us and our tenants, operators and borrowers from current and future litigation matters, including the possibility of larger than expected litigation costs, adverse results and related developments; changes in federal, state or local laws and regulations, including those affecting the healthcare industry that affect our costs of compliance or increase the costs, or otherwise affect the operations, of our tenants and operators; our ability to foreclose on collateral securing our real estate-related loans; volatility or uncertainty in the capital markets, the availability and cost of capital as impacted by interest rates, changes in our credit ratings, the value of our common stock, and other conditions that may adversely impact our ability to fund our obligations or consummate transactions, or reduce the earnings from potential transactions; changes in global, national and local economic and other conditions, including the ongoing economic downturn, volatility in the financial markets and high unemployment rates; our ability to manage our indebtedness level and changes in the terms of such indebtedness; competition for skilled management and other key personnel; our reliance on information technology systems and the potential impact of system failures, disruptions or breaches; our ability to maintain our qualification as a real estate investment trust; and other risks and uncertainties described from time to time in our
CONTACT
Barbat Rodgers
Senior Director – Investor Relations
949-407-0400
|
|
||||||||
|
Consolidated Balance Sheets |
||||||||
|
In thousands, except share and per share data |
||||||||
|
(unaudited) |
||||||||
|
|
|
|||||||
|
Assets |
||||||||
|
Real estate: |
||||||||
|
Buildings and improvements |
$ |
10,967,446 |
$ |
11,120,039 |
||||
|
Development costs and construction in progress |
684,979 |
692,336 |
||||||
|
Land |
1,889,643 |
1,992,602 |
||||||
|
Accumulated depreciation and amortization |
(2,507,881) |
(2,771,922) |
||||||
|
Net real estate |
11,034,187 |
11,033,055 |
||||||
|
Net investment in direct financing leases |
44,706 |
84,604 |
||||||
|
Loans receivable, net of reserves of |
231,162 |
190,579 |
||||||
|
Investments in and advances to unconsolidated joint ventures |
436,271 |
825,515 |
||||||
|
Accounts receivable, net of allowance of |
63,216 |
59,417 |
||||||
|
Cash and cash equivalents |
197,119 |
144,232 |
||||||
|
Restricted cash |
102,419 |
40,425 |
||||||
|
Intangible assets, net |
501,583 |
331,693 |
||||||
|
Assets held for sale, net |
2,213,185 |
504,394 |
||||||
|
Right-of-use asset, net |
190,875 |
172,486 |
||||||
|
Other assets, net |
737,098 |
646,491 |
||||||
|
Total assets |
$ |
15,751,821 |
$ |
14,032,891 |
||||
|
Liabilities and Equity |
||||||||
|
Bank line of credit and commercial paper |
$ |
— |
$ |
93,000 |
||||
|
Term loan |
249,122 |
248,942 |
||||||
|
Senior unsecured notes |
5,695,567 |
5,647,993 |
||||||
|
Mortgage debt |
435,206 |
276,907 |
||||||
|
Intangible liabilities, net |
108,031 |
74,991 |
||||||
|
Liabilities related to assets held for sale, net |
93,046 |
36,369 |
||||||
|
Lease liability |
175,002 |
156,611 |
||||||
|
Accounts payable, accrued liabilities, and other liabilities |
834,518 |
540,924 |
||||||
|
Deferred revenue |
755,021 |
289,680 |
||||||
|
Total liabilities |
8,345,513 |
7,365,417 |
||||||
|
Commitments and contingencies |
||||||||
|
Common stock, |
538,355 |
505,222 |
||||||
|
Additional paid-in capital |
10,228,086 |
9,183,892 |
||||||
|
Cumulative dividends in excess of earnings |
(3,923,150) |
(3,601,199) |
||||||
|
Accumulated other comprehensive income (loss) |
(3,236) |
(2,857) |
||||||
|
Total stockholders' equity |
6,840,055 |
6,085,058 |
||||||
|
Joint venture partners |
366,708 |
378,061 |
||||||
|
Non-managing member unitholders |
199,545 |
204,355 |
||||||
|
Total noncontrolling interests |
566,253 |
582,416 |
||||||
|
Total equity |
7,406,308 |
6,667,474 |
||||||
|
Total liabilities and equity |
$ |
15,751,821 |
$ |
14,032,891 |
||||
|
|
||||||||||||||||
|
Consolidated Statements of Operations |
||||||||||||||||
|
In thousands, except per share data |
||||||||||||||||
|
(unaudited) |
||||||||||||||||
|
Three Months Ended |
Nine Months Ended |
|||||||||||||||
|
2020 |
2019 |
2020 |
2019 |
|||||||||||||
|
Revenues: |
||||||||||||||||
|
Rental and related revenues |
$ |
326,530 |
$ |
312,600 |
$ |
953,581 |
$ |
908,019 |
||||||||
|
Resident fees and services |
264,616 |
213,040 |
797,818 |
517,501 |
||||||||||||
|
Income from direct financing leases |
2,150 |
9,590 |
7,569 |
33,304 |
||||||||||||
|
Interest income |
4,443 |
2,741 |
12,361 |
6,868 |
||||||||||||
|
Total revenues |
597,739 |
537,971 |
1,771,329 |
1,465,692 |
||||||||||||
|
Costs and expenses: |
||||||||||||||||
|
Interest expense |
56,235 |
61,230 |
172,161 |
167,499 |
||||||||||||
|
Depreciation and amortization |
173,630 |
171,944 |
541,394 |
469,191 |
||||||||||||
|
Operating |
314,292 |
248,069 |
1,006,146 |
630,989 |
||||||||||||
|
General and administrative |
21,661 |
22,970 |
67,730 |
71,445 |
||||||||||||
|
Transaction costs |
2,586 |
1,319 |
18,061 |
7,174 |
||||||||||||
|
Impairments and loan loss reserves (recoveries), net |
34,550 |
38,257 |
97,723 |
115,653 |
||||||||||||
|
Total costs and expenses |
602,954 |
543,789 |
1,903,215 |
1,461,951 |
||||||||||||
|
Other income (expense): |
||||||||||||||||
|
Gain (loss) on sales of real estate, net |
149 |
(784) |
247,881 |
18,708 |
||||||||||||
|
Loss on debt extinguishments |
(17,921) |
(35,017) |
(42,912) |
(36,152) |
||||||||||||
|
Other income (expense), net |
7,060 |
693 |
237,254 |
24,834 |
||||||||||||
|
Total other income (expense), net |
(10,712) |
(35,108) |
442,223 |
7,390 |
||||||||||||
|
Income (loss) before income taxes and equity income (loss) from unconsolidated joint ventures |
(15,927) |
(40,926) |
310,337 |
11,131 |
||||||||||||
|
Income tax benefit (expense) |
(24,174) |
6,261 |
16,216 |
11,583 |
||||||||||||
|
Equity income (loss) from unconsolidated joint ventures |
(19,480) |
(7,643) |
(48,545) |
(10,012) |
||||||||||||
|
Net income (loss) |
(59,581) |
(42,308) |
278,008 |
12,702 |
||||||||||||
|
Noncontrolling interests' share in earnings |
(3,836) |
(3,555) |
(10,839) |
(10,692) |
||||||||||||
|
Net income (loss) attributable to |
(63,417) |
(45,863) |
267,169 |
2,010 |
||||||||||||
|
Participating securities' share in earnings |
(351) |
(386) |
(2,151) |
(1,223) |
||||||||||||
|
Net income (loss) applicable to common shares |
$ |
(63,768) |
$ |
(46,249) |
$ |
265,018 |
$ |
787 |
||||||||
|
Earnings per common share: |
||||||||||||||||
|
Basic |
$ |
(0.12) |
$ |
(0.09) |
$ |
0.50 |
$ |
0.00 |
||||||||
|
Diluted |
$ |
(0.12) |
$ |
(0.09) |
$ |
0.50 |
$ |
0.00 |
||||||||
|
Weighted average shares outstanding: |
||||||||||||||||
|
Basic |
538,333 |
491,203 |
527,908 |
482,595 |
||||||||||||
|
Diluted |
538,333 |
491,203 |
528,455 |
484,792 |
||||||||||||
|
|
|||||||||||||||||
|
Funds From Operations |
|||||||||||||||||
|
In thousands, except per share data |
|||||||||||||||||
|
(unaudited) |
|||||||||||||||||
|
Three Months Ended |
Nine Months Ended |
||||||||||||||||
|
2020 |
2019 |
2020 |
2019 |
||||||||||||||
|
Net income (loss) applicable to common shares |
$ |
(63,768) |
$ |
(46,249) |
$ |
265,018 |
$ |
787 |
|||||||||
|
Real estate related depreciation and amortization |
173,630 |
171,944 |
541,394 |
469,191 |
|||||||||||||
|
Healthpeak's share of real estate related depreciation and amortization from unconsolidated joint ventures |
24,822 |
14,952 |
80,050 |
45,153 |
|||||||||||||
|
Noncontrolling interests' share of real estate related depreciation and amortization |
(5,020) |
(4,999) |
(15,043) |
(14,927) |
|||||||||||||
|
Other real estate-related depreciation and amortization |
319 |
1,357 |
2,447 |
4,798 |
|||||||||||||
|
Loss (gain) on sales of depreciable real estate, net |
(149) |
784 |
(247,881) |
(18,708) |
|||||||||||||
|
Healthpeak's share of loss (gain) on sales of real estate, net, from unconsolidated joint ventures |
— |
— |
(9,248) |
— |
|||||||||||||
|
Noncontrolling interests' share of gain (loss) on sales of real estate, net |
— |
(2) |
(3) |
206 |
|||||||||||||
|
Loss (gain) upon change of control, net(1) |
(3,259) |
20 |
(173,222) |
(11,481) |
|||||||||||||
|
Taxes associated with real estate dispositions |
551 |
— |
(10,989) |
— |
|||||||||||||
|
Impairments (recoveries) of depreciable real estate, net(2) |
37,477 |
43,784 |
85,996 |
111,033 |
|||||||||||||
|
NAREIT FFO applicable to common shares |
164,603 |
181,591 |
518,519 |
586,052 |
|||||||||||||
|
Distributions on dilutive convertible units and other |
— |
1,675 |
5,380 |
4,954 |
|||||||||||||
|
Diluted NAREIT FFO applicable to common shares |
$ |
164,603 |
$ |
183,266 |
$ |
523,899 |
$ |
591,006 |
|||||||||
|
Diluted NAREIT FFO per common share |
$ |
0.31 |
$ |
0.37 |
$ |
0.98 |
$ |
1.21 |
|||||||||
|
Weighted average shares outstanding - diluted NAREIT FFO |
538,645 |
499,450 |
533,963 |
489,609 |
|||||||||||||
|
Impact of adjustments to NAREIT FFO: |
|||||||||||||||||
|
Transaction-related items(3) |
$ |
2,276 |
$ |
1,335 |
$ |
95,342 |
$ |
13,659 |
|||||||||
|
Other impairments (recoveries) and other losses (gains), net(4) |
(2,927) |
— |
(29,943) |
10,147 |
|||||||||||||
|
Severance and related charges |
— |
1,334 |
— |
5,063 |
|||||||||||||
|
Loss on debt extinguishments |
17,921 |
35,017 |
42,912 |
36,152 |
|||||||||||||
|
Litigation costs (recoveries) |
26 |
(150) |
232 |
(549) |
|||||||||||||
|
Casualty-related charges (recoveries), net |
469 |
1,607 |
469 |
(4,636) |
|||||||||||||
|
Foreign currency remeasurement losses (gains) |
— |
(162) |
153 |
(350) |
|||||||||||||
|
Valuation allowance on deferred tax assets(5) |
31,161 |
— |
31,161 |
— |
|||||||||||||
|
Tax rate legislation impact(6) |
— |
— |
(3,590) |
— |
|||||||||||||
|
Total adjustments |
48,926 |
38,981 |
136,736 |
59,486 |
|||||||||||||
|
FFO as Adjusted applicable to common shares |
213,529 |
220,572 |
655,255 |
645,538 |
|||||||||||||
|
Distributions on dilutive convertible units and other |
1,852 |
1,588 |
5,244 |
4,809 |
|||||||||||||
|
Diluted FFO as Adjusted applicable to common shares |
$ |
215,381 |
$ |
222,160 |
$ |
660,499 |
$ |
650,347 |
|||||||||
|
Diluted FFO as Adjusted per common share |
$ |
0.40 |
$ |
0.44 |
$ |
1.24 |
$ |
1.33 |
|||||||||
|
Weighted average shares outstanding - diluted FFO as Adjusted |
544,146 |
499,450 |
533,963 |
489,609 |
|||||||||||||
|
_______________________________________ |
||
|
(1) |
For the nine months ended |
|
|
(2) |
For the three and nine months ended |
|
|
(3) |
For the nine months ended |
|
|
(4) |
For the three and nine months ended |
|
|
(5) |
For the three and nine months ended |
|
|
(6) |
For the nine months ended |
|
|
|
||||||||||||||||
|
Adjusted Funds From Operations |
||||||||||||||||
|
In thousands |
||||||||||||||||
|
(unaudited) |
||||||||||||||||
|
Three Months Ended |
Nine Months Ended |
|||||||||||||||
|
2020 |
2019 |
2020 |
2019 |
|||||||||||||
|
FFO as Adjusted applicable to common shares |
$ |
213,529 |
$ |
220,572 |
$ |
655,255 |
$ |
645,538 |
||||||||
|
Amortization of deferred compensation |
4,420 |
3,715 |
13,392 |
11,613 |
||||||||||||
|
Amortization of deferred financing costs |
2,554 |
2,735 |
7,670 |
8,174 |
||||||||||||
|
Straight-line rents |
(9,542) |
(10,252) |
(24,086) |
(22,192) |
||||||||||||
|
AFFO capital expenditures |
(20,756) |
(24,107) |
(61,329) |
(62,840) |
||||||||||||
|
Lease restructure payments |
347 |
289 |
966 |
870 |
||||||||||||
|
CCRC entrance fees(1) |
— |
5,731 |
— |
14,071 |
||||||||||||
|
Deferred income taxes |
(7,300) |
(6,434) |
(9,200) |
(14,063) |
||||||||||||
|
Other AFFO adjustments(2) |
539 |
(2,002) |
675 |
(4,387) |
||||||||||||
|
AFFO applicable to common shares |
183,791 |
190,247 |
583,343 |
576,784 |
||||||||||||
|
Distributions on dilutive convertible units and other |
— |
1,675 |
5,380 |
4,953 |
||||||||||||
|
Diluted AFFO applicable to common shares |
$ |
183,791 |
$ |
191,922 |
$ |
588,723 |
$ |
581,737 |
||||||||
|
Weighted average shares outstanding - diluted AFFO |
538,645 |
499,450 |
533,963 |
489,609 |
||||||||||||
|
_______________________________________ |
||
|
(1) |
In connection with the acquisition of the remaining 51% interest in the CCRC JV in |
|
|
(2) |
Primarily includes our share of AFFO capital expenditures from unconsolidated joint ventures, partially offset by noncontrolling interests' share of AFFO capital expenditures from consolidated joint ventures. |
|

View original content:http://www.prnewswire.com/news-releases/healthpeak-properties-reports-third-quarter-2020-results-301165055.html
SOURCE



Satellite Insurance Market to Witness Huge Growth by 2025 : Allianz, Travers Aviation, AXA
Group Personal Accident Insurance Market to Witness Huge Growth by 2025 : Allianz, AXA, Gerber Life Insurance
Advisor News
- LTC: A critical component of retirement planning
- Middle-class households face worsening cost pressures
- Metlife study finds less than half of US workforce holistically healthy
- Invigorating client relationships with AI coaching
- SEC: Get-rich-quick influencer Tai Lopez was running a Ponzi scam
More Advisor NewsAnnuity News
- The structural rise of structured products
- How next-gen pricing tech can help insurers offer better annuity products
- Continental General Acquires Block of Life Insurance, Annuity and Health Policies from State Guaranty Associations
- Lincoln reports strong life/annuity sales, executes with ‘discipline and focus’
- LIMRA launches the Lifetime Income Initiative
More Annuity NewsHealth/Employee Benefits News
- Plainfield, Vermont Man Sentenced to 2 Years of Probation for Social Security Disability Fraud
- LTC: A critical component of retirement planning
- Pennsylvanians urged to prioritize health
- PLAINFIELD, VERMONT MAN SENTENCED TO 2 YEARS OF PROBATION FOR SOCIAL SECURITY DISABILITY FRAUD
- Broward schools cut coverage of weight-loss drugs to save $12 million
More Health/Employee Benefits NewsLife Insurance News